FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Res / Equine sarcoids: Bovine Papillomavirus type 1 transformed fi...
Veterinary research2012; 43(1); 81; doi: 10.1186/1297-9716-43-81

Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53.

Abstract: Bovine papillomavirus type 1 infects not only cattle but also equids and is a causative factor in the pathogenesis of commonly occurring equine sarcoid tumours. Whilst treatment of sarcoids is notoriously difficult, cisplatin has been shown to be one of the most effective treatment strategies for sarcoids. In this study we show that in equine fibroblasts, BPV-1 sensitises cells to cisplatin-induced and UVB-induced apoptosis, a known cofactor for papillomavirus associated disease, however BPV-1 transformed fibroblasts show increased clonogenic survival, which may potentially limit the therapeutic effects of repeated cisplatin treatment. Furthermore we show that BPV-1 increases p53 expression in sarcoid cell lines and p53 expression can be either nuclear or cytoplasmic. The mechanism and clinical significance of increase/abnormal p53 expression remains to be established.
Get Full Text
Publication Date: 2012-12-04 PubMed ID: 23210796PubMed Central: PMC3557224DOI: 10.1186/1297-9716-43-81Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research evaluates the sensitivity of horse sarcoid tumors, caused by Bovine Papillomavirus type 1 (BPV-1), to apoptosis induced by cisplatin and UVB. It further investigates the aberrant expression of p53 in affected fibroblasts.

Study Objective and Methodology

  • The purpose of this scientific study revolves around understanding the effects of Bovine Papillomavirus type 1 (BPV-1) infection in horses that results in equine sarcoid tumours.
  • The research also investigates the potential efficiency of cisplatin as a treatment strategy for sarcoids.
  • Cisplatin and UVB-induced apoptosis (programmed cell death) of equine fibroblasts was studied.
  • The scientists also investigated whether BPV-1 transformed fibroblasts showcase increased clonogenic survival, a condition that could possibly limit the therapeutic effects of consecutive cisplatin treatments.
  • Finally, the research also focuses on the abnormal increase of p53 expression in sarcoid cell lines in correlation with the BPV-1.

Key Findings

  • The findings of this research suggest that in equine fibroblasts, BPV-1 predisposes cells to be more susceptible to apoptosis induced by both cisplatin and UVB, a known contributor to papillomavirus-associated disease. Therefore, cisplatin emerges as potentially effective in the treatment of equine sarcoid tumours caused by BPV-1.
  • However, an increased clonogenic survival capacity was observed in BPV-1 transformed fibroblasts, suggesting that this might limit the effectiveness of repeated cisplatin treatment.
  • Another key finding was that BPV-1 can cause an increase in p53 expression in sarcoid cell lines. P53 is a protein coded by the TP53 gene in humans and is a crucial player in preventing cancer. Increased or abnormal P53 protein could signify an interruption in regular cell cycling and apoptosis, potentially leading to hyperproliferative diseases such as cancer.
  • The authors note, however, that the mechanism and clinical significance of this heightened or abnormal p53 expression need to be further investigated and established.

Implications

  • This research contributes significantly to understanding of equine sarcoid tumours, as it offers insights about the sensitivity of BPV-1 transformed fibroblasts to apoptosis induced by cisplatin and UVB.
  • While the study suggests a potential limitation in the effectiveness of repeated cisplatin treatment due to increased clonogenic survival, it nonetheless supports cisplatin as a viable treatment strategy.
  • The study’s investigation into p53 expression presents a plausible start point for further research into the mechanisms and clinical implications of abnormal p53 expression in sarcoid cell lines due to BPV-1.

Cite This Article

APA
Finlay M, Yuan Z, Morgan IM, Campo MS, Nasir L. (2012). Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53. Vet Res, 43(1), 81. https://doi.org/10.1186/1297-9716-43-81

Publication

Veterinary research
ISSN: 1297-9716
NlmUniqueID: 9309551
Country: England
Language: English
Volume: 43
Issue: 1
Pages: 81

Researcher Affiliations

Finlay, Margaret
  • MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Inflammation and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Bearsden Road, Glasgow, Scotland, G61 1QH, United Kingdom. Lubna.Nasir@gla.ac.uk.
Yuan, Zhengqiang
    Morgan, Iain M
      Campo, M Saveria
        Nasir, Lubna

          MeSH Terms

          • Animals
          • Antineoplastic Agents / administration & dosage
          • Antineoplastic Agents / pharmacology
          • Apoptosis / drug effects
          • Blotting, Western / veterinary
          • Bovine papillomavirus 1 / physiology
          • Cisplatin / administration & dosage
          • Cisplatin / pharmacology
          • Fibroblasts / virology
          • Gene Expression Regulation
          • Horse Diseases / genetics
          • Horse Diseases / virology
          • Horses
          • Papillomavirus Infections / genetics
          • Papillomavirus Infections / veterinary
          • Papillomavirus Infections / virology
          • Tumor Suppressor Protein p53 / genetics
          • Tumor Suppressor Protein p53 / metabolism
          • Ultraviolet Rays

          References

          This article includes 60 references
          1. Jackson C. The incidence and pathology of tumours of domesticated animals in South Africa.. Onderstepoort J Vet Sci Animal Indust 1936;6:378–385.
          2. Pascoe RR, Summers PM. Clinical survey of tumours and tumour-like lesions in horses in south east Queensland.. Equine Vet J 1981 Oct;13(4):235-9.
            doi: 10.1111/j.2042-3306.1981.tb03504.xpubmed: 6459231google scholar: lookup
          3. Ragland KWL, Keown GFH, Spencer GR. Equine Sarcoid.. Equine Vet J 1970;2:2–11.
            doi: 10.1111/j.2042-3306.1970.tb04145.xgoogle scholar: lookup
          4. Marti E, Lazary S, Antczak DF, Gerber H. Report of the first international workshop on equine sarcoid.. Equine Vet J 1993 Sep;25(5):397-407.
            doi: 10.1111/j.2042-3306.1993.tb02981.xpubmed: 8223371google scholar: lookup
          5. Goodrich L, Gerber H, Marti E, Antczak DF. Equine sarcoids.. Vet Clin North Am Equine Pract 1998 Dec;14(3):607-23, vii.
            pubmed: 9891727doi: 10.1016/s0749-0739(17)30189-xgoogle scholar: lookup
          6. Marais HJ, Nel P, Bertschinger HJ, Schoeman JP, Zimmerman D. Prevalence and body distribution of sarcoids in South African Cape mountain zebra (Equus zebra zebra).. J S Afr Vet Assoc 2007 Sep;78(3):145-8.
            pubmed: 18237037doi: 10.4102/jsava.v78i3.306google scholar: lookup
          7. Knottenbelt DC. A suggested clinical classification for the equine sarcoid.. Clin Tech Eq Prac 2005;4:278–295.
            doi: 10.1053/j.ctep.2005.10.008google scholar: lookup
          8. Martens A, De Moor A, Demeulemeester J, Peelman L. Polymerase chain reaction analysis of the surgical margins of equine sarcoids for bovine papilloma virus DNA.. Vet Surg 2001 Sep-Oct;30(5):460-7.
            doi: 10.1053/jvet.2001.25874pubmed: 11555822google scholar: lookup
          9. Tarwid JN, Fretz PB, Clark EG. Equine sarcoids: a study with emphasis on pathological diagnosis.. Comp Cont Educ Pract 1985;7:293–300.
          10. Lane JG. The treatment of equine sarcoids by cryosurgery.. Equine Vet J 1977 Jul;9(3):127-33.
            doi: 10.1111/j.2042-3306.1977.tb04003.xpubmed: 891516google scholar: lookup
          11. Vingerhoets M, Diehl M, Gerber H, Stornetta D, Rausis C. [The treatment of equine sarcoidosis by carbon dioxide laser].. Schweiz Arch Tierheilkd 1988 Mar;130(3):113-26.
            pubmed: 3375796
          12. Knottenbelt DC, Kelly DF. The diagnosis and treatment of periorbital sarcoid in the horse: 445 cases from 1974 to 1999.. Vet Ophthalmol 2000;3(2-3):169-191.
            doi: 10.1046/j.1463-5224.2000.00119.xpubmed: 11397301google scholar: lookup
          13. Palmer SE. Treatment of common cutaneous tumors using the carbon dioxide laser.. Clin Tech equine Pract 2002;1:43–50.
            doi: 10.1053/ctep.2002.33171google scholar: lookup
          14. Nogueira SA, Torres SM, Malone ED, Diaz SF, Jessen C, Gilbert S. Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study.. Vet Dermatol 2006 Aug;17(4):259-65.
            doi: 10.1111/j.1365-3164.2006.00526.xpubmed: 16827669google scholar: lookup
          15. Stadler S, Kainzbauer C, Haralambus R, Brehm W, Hainisch E, Brandt S. Successful treatment of equine sarcoids by topical aciclovir application.. Vet Rec 2011 Feb 19;168(7):187.
            doi: 10.1136/vr.c5430pubmed: 21493530google scholar: lookup
          16. Knottenbelt DC, Walker JA. Topical treatment of the equine sarcoid.. Equine Vet Ed 1994;6:72–75.
            doi: 10.1111/j.2042-3292.1994.tb01089.xgoogle scholar: lookup
          17. Knottenbelt DC, Edwards SER, Daniel EA. The diagnosis and treatment of equine sarcoids.. In Practice 1995;17:123–129.
            doi: 10.1136/inpract.17.3.123google scholar: lookup
          18. Nasir L, Campo MS. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids.. Vet Dermatol 2008 Oct;19(5):243-54.
            doi: 10.1111/j.1365-3164.2008.00683.xpubmed: 18927950google scholar: lookup
          19. Campo MS. Bovine papillomavirus: Old system, new lessons?. In: Papillomavirus Research: From Natural History to Vaccines and Beyond. Campo MS, editor. Wymondham: England Caister Academic Press; 2006. pp. 373–387.
          20. Ashrafi GH, Piuko K, Burden F, Yuan Z, Gault EA, Müller M, Trawford A, Reid SWJ, Nasir L, Campo MS. Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1.. J Gen Virol 2008 Jan;89(Pt 1):148-157.
            doi: 10.1099/vir.0.83267-0pubmed: 18089738google scholar: lookup
          21. Gobeil PA, Yuan Z, Gault EA, Morgan IM, Campo MS, Nasir L. Small interfering RNA targeting bovine papillomavirus type 1 E2 induces apoptosis in equine sarcoid transformed fibroblasts.. Virus Res 2009 Oct;145(1):162-5.
            doi: 10.1016/j.virusres.2009.06.019pubmed: 19615418google scholar: lookup
          22. Yuan Z, Gault EA, Campo MS, Nasir L. Different contribution of bovine papillomavirus type 1 oncoproteins to the transformation of equine fibroblasts.. J Gen Virol 2011 Apr;92(Pt 4):773-83.
            doi: 10.1099/vir.0.028191-0pubmed: 21177927google scholar: lookup
          23. Yuan ZQ, Gault EA, Gobeil P, Nixon C, Campo MS, Nasir L. Establishment and characterization of equine fibroblast cell lines transformed in vivo and in vitro by BPV-1: model systems for equine sarcoids.. Virology 2008 Apr 10;373(2):352-61.
            doi: 10.1016/j.virol.2007.11.037pubmed: 18191170google scholar: lookup
          24. Marchetti B, Gault EA, Cortese MS, Yuan Z, Ellis SA, Nasir L, Campo MS. Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain.. J Gen Virol 2009 Dec;90(Pt 12):2865-2870.
            doi: 10.1099/vir.0.014746-0pubmed: 19675187google scholar: lookup
          25. Yuan ZQ, Bennett L, Campo MS, Nasir L. Bovine papillomavirus type 1 E2 and E7 proteins down-regulate Toll Like Receptor 4 (TLR4) expression in equine fibroblasts.. Virus Res 2010 Apr;149(1):124-7.
            doi: 10.1016/j.virusres.2010.01.008pubmed: 20109504google scholar: lookup
          26. Yuan Z, Gobeil PA, Campo MS, Nasir L. Equine sarcoid fibroblasts over-express matrix metalloproteinases and are invasive.. Virology 2010 Jan 5;396(1):143-51.
            doi: 10.1016/j.virol.2009.10.010pubmed: 19896685google scholar: lookup
          27. Yuan Z, Gault EA, Campo MS, Nasir L. Upregulation of equine matrix metalloproteinase 1 by bovine papillomavirus type 1 is through the transcription factor activator protein-1.. J Gen Virol 2011 Nov;92(Pt 11):2608-2619.
            doi: 10.1099/vir.0.033431-0pubmed: 21775582google scholar: lookup
          28. Yuan Z, Gault EA, Campo MS, Nasir L. p38 mitogen-activated protein kinase is crucial for bovine papillomavirus type-1 transformation of equine fibroblasts.. J Gen Virol 2011 Aug;92(Pt 8):1778-1786.
            doi: 10.1099/vir.0.031526-0pubmed: 21471309google scholar: lookup
          29. Théon AP, Pascoe JR, Carlson GP, Krag DN. Intratumoral chemotherapy with cisplatin in oily emulsion in horses.. J Am Vet Med Assoc 1993 Jan 15;202(2):261-7.
            pubmed: 8428832
          30. Hewes CA, Sullins KE. Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004).. J Am Vet Med Assoc 2006 Nov 15;229(10):1617-22.
            doi: 10.2460/javma.229.10.1617pubmed: 17107319google scholar: lookup
          31. Tamzali Y, Borde L, Rols MP, Golzio M, Lyazrhi F, Teissie J. Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases.. Equine Vet J 2012 Mar;44(2):214-20.
            doi: 10.1111/j.2042-3306.2011.00425.xpubmed: 21793876google scholar: lookup
          32. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance.. Oncogene 2003 Oct 20;22(47):7265-79.
            doi: 10.1038/sj.onc.1206933pubmed: 14576837google scholar: lookup
          33. Hernández Losa J, Parada Cobo C, Guinea Viniegra J, Sánchez-Arevalo Lobo VJ, Ramón y Cajal S, Sánchez-Prieto R. Role of the p38 MAPK pathway in cisplatin-based therapy.. Oncogene 2003 Jun 26;22(26):3998-4006.
            doi: 10.1038/sj.onc.1206608pubmed: 12821934google scholar: lookup
          34. Pfister H. Human papillomaviruses and skin cancer.. Semin Cancer Biol 1992 Oct;3(5):263-71.
            pubmed: 1335790
          35. Jackson S, Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage.. Oncogene 2000 Jan 27;19(4):592-8.
            doi: 10.1038/sj.onc.1203339pubmed: 10698529google scholar: lookup
          36. McCauley CT, Hawkins JF, Adams SB, Fessler JF. Use of a carbon dioxide laser for surgical management of cutaneous masses in horses: 32 cases (1993-2000).. J Am Vet Med Assoc 2002 Apr 15;220(8):1192-7.
            doi: 10.2460/javma.2002.220.1192pubmed: 11990967google scholar: lookup
          37. Carstanjen B, Jordan P, Lepage OM. Carbon dioxide laser as a surgical instrument for sarcoid therapy--a retrospective study on 60 cases.. Can Vet J 1997 Dec;38(12):773-6.
            pmc: PMC1576782pubmed: 9426943
          38. Taylor ER, Boner W, Dornan ES, Corr EM, Morgan IM. UVB irradiation reduces the half-life and transactivation potential of the human papillomavirus 16 E2 protein.. Oncogene 2003 Jul 17;22(29):4469-77.
            doi: 10.1038/sj.onc.1206746pubmed: 12881703google scholar: lookup
          39. Théon AP. Intralesional and topical chemotherapy and immunotherapy.. Vet Clin North Am Equine Pract 1998 Dec;14(3):659-71, viii.
            pubmed: 9891729doi: 10.1016/s0749-0739(17)30191-8google scholar: lookup
          40. Théon AP, Pascoe JR, Meagher DM. Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumors in equidae.. J Am Vet Med Assoc 1994 Oct 15;205(8):1170-6.
            pubmed: 7890578
          41. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein.. Curr Opin Cell Biol 2001 Jun;13(3):332-7.
            doi: 10.1016/S0955-0674(00)00216-7pubmed: 11343904google scholar: lookup
          42. Rogel A, Popliker M, Webb CG, Oren M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors.. Mol Cell Biol 1985 Oct;5(10):2851-5.
            pmc: PMC367026pubmed: 3915536doi: 10.1128/mcb.5.10.2851-2855.1985google scholar: lookup
          43. Bucher K, Szalai G, Marti E, Griot-Wenk ME, Lazary S, Pauli U. Tumour suppressor gene p53 in the horse: identification, cloning, sequencing and a possible role in the pathogenesis of equine sarcoid.. Res Vet Sci 1996 Sep;61(2):114-9.
            doi: 10.1016/S0034-5288(96)90084-3pubmed: 8880979google scholar: lookup
          44. Nasir L, Mcfarlane ST, Reid SW. Mutational status of the tumour suppressor gene (p53) in donkey sarcoid tumours.. Vet J 1999 Jan;157(1):99-101.
            doi: 10.1053/tvjl.1998.0266pubmed: 10030136google scholar: lookup
          45. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.. Oncogene 1997 Sep 4;15(10):1179-89.
            doi: 10.1038/sj.onc.1201459pubmed: 9294611google scholar: lookup
          46. Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.. Cancer Res 1998 Jan 15;58(2):328-33.
            pubmed: 9443413
          47. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2.. Nature 1997 May 15;387(6630):299-303.
            doi: 10.1038/387299a0pubmed: 9153396google scholar: lookup
          48. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT, Zhang N. mdmx is a negative regulator of p53 activity in vivo.. Cancer Res 2002 Jun 1;62(11):3221-5.
            pubmed: 12036937
          49. Yamauchi M, Suzuki K, Kodama S, Watanabe M. Abnormal stability of wild-type p53 protein in a human lung carcinoma cell line.. Biochem Biophys Res Commun 2005 May 6;330(2):483-8.
            doi: 10.1016/j.bbrc.2004.11.174pubmed: 15796908google scholar: lookup
          50. Eichten A, Westfall M, Pietenpol JA, Münger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein.. Virology 2002 Mar 30;295(1):74-85.
            doi: 10.1006/viro.2002.1375pubmed: 12033767google scholar: lookup
          51. Moll UM, LaQuaglia M, Bénard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.. Proc Natl Acad Sci U S A 1995 May 9;92(10):4407-11.
            doi: 10.1073/pnas.92.10.4407pmc: PMC41953pubmed: 7753819google scholar: lookup
          52. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.. Proc Natl Acad Sci U S A 1992 Aug 1;89(15):7262-6.
            doi: 10.1073/pnas.89.15.7262pmc: PMC49686pubmed: 1353891google scholar: lookup
          53. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage.. Mol Cell Biol 1996 Mar;16(3):1126-37.
            pmc: PMC231095pubmed: 8622657doi: 10.1128/mcb.16.3.1126google scholar: lookup
          54. Wang X, Zalcenstein A, Oren M. Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation.. Cell Death Differ 2003 Apr;10(4):468-76.
            doi: 10.1038/sj.cdd.4401181pubmed: 12719724google scholar: lookup
          55. Oh W, Lee EW, Sung YH, Yang MR, Ghim J, Lee HW, Song J. Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2.. J Biol Chem 2006 Jun 23;281(25):17457-17465.
            doi: 10.1074/jbc.M601857200pubmed: 16624822google scholar: lookup
          56. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53.. Cell 2003 Jan 10;112(1):29-40.
            pubmed: 12526791doi: 10.1016/s0092-8674(02)01255-2google scholar: lookup
          57. Martens A, De Moor A, Demeulemeester J, Ducatelle R. Histopathological characteristics of five clinical types of equine sarcoid.. Res Vet Sci 2000 Dec;69(3):295-300.
            doi: 10.1053/rvsc.2000.0432pubmed: 11124103google scholar: lookup
          58. Bogaert L, Van Poucke M, De Baere C, Dewulf J, Peelman L, Ducatelle R, Gasthuys F, Martens A. Bovine papillomavirus load and mRNA expression, cell proliferation and p53 expression in four clinical types of equine sarcoid.. J Gen Virol 2007 Aug;88(Pt 8):2155-2161.
            doi: 10.1099/vir.0.82876-0pubmed: 17622617google scholar: lookup
          59. Johnston HM, Thompson H, Pirie HM. p53 immunohistochemistry in domestic animal tumours.. Eur J Vet Pathol 1996;2:135–140.
          60. Nixon C, Chambers G, Ellsmore V, Campo MS, Burr P, Argyle DJ, Reid SW, Nasir L. Expression of cell cycle associated proteins cyclin A, CDK-2, p27kip1 and p53 in equine sarcoids.. Cancer Lett 2005 Apr 28;221(2):237-45.
            doi: 10.1016/j.canlet.2004.08.039pubmed: 15808409google scholar: lookup

          Citations

          This article has been cited 10 times.
          1. Cacciotto C, Dore GM, Anfossi AG, Tore G, Varoni MV, Demontis MP, Antuofermo E, Pittau M, Alberti A. Development of immunodiagnostic tools for in situ investigation of Ovis aries papillomavirus 3 (OaPV3).. Vet Res Commun 2023 Jun;47(2):641-649.
            doi: 10.1007/s11259-022-10018-5pubmed: 36331789google scholar: lookup
          2. Tura G, Brunetti B, Brigandì E, Rinnovati R, Sarli G, Avallone G, Muscatello LV, La Ragione RM, Durham AE, Bacci B. Expression of Cell-Cycle Regulatory Proteins pRb, Cyclin D1, and p53 Is Not Associated with Recurrence Rates of Equine Sarcoids.. Vet Sci 2022 Sep 1;9(9).
            doi: 10.3390/vetsci9090474pubmed: 36136690google scholar: lookup
          3. Emin K, Nuvit C, Serpil D, Enver B, Ataseven VS, Volkan Y, Fırat D, Hilmi N, Celal Sahin E, Ugur A, Mushap K, Ayfer Y. Molecular detection of Papillomavirus and immunohistochemical investigation of p53 gene expressions in bovine papillomas and fibropapillomas.. Arch Microbiol 2022 Apr 24;204(5):278.
            doi: 10.1007/s00203-022-02902-0pubmed: 35461436google scholar: lookup
          4. Al-Salihi KA, Al-Dabhawi AH, Ajeel AA, Erzuki IA, Ali TAH. Clinico-Histopathological and Immunohistochemical Study of Ruminant's Cutaneous Papillomavirus in Iraq.. Vet Med Int 2020;2020:5691974.
            doi: 10.1155/2020/5691974pubmed: 32148749google scholar: lookup
          5. Greenwood S, Campbell O, Movasseghi AR. Oral sarcoid in a cat.. Can Vet J 2019 May;60(5):485-489.
            pubmed: 31080260
          6. Barreto DM, Barros GS, Santos LABO, Soares RC, Batista MVA. Comparative transcriptomic analysis of bovine papillomatosis.. BMC Genomics 2018 Dec 19;19(1):949.
            doi: 10.1186/s12864-018-5361-ypubmed: 30567500google scholar: lookup
          7. Thaiwong T, Sledge DG, Wise AG, Olstad K, Maes RK, Kiupel M. Malignant transformation of canine oral papillomavirus (CPV1)-associated papillomas in dogs: An emerging concern?. Papillomavirus Res 2018 Dec;6:83-89.
            doi: 10.1016/j.pvr.2018.10.007pubmed: 30414951google scholar: lookup
          8. Fornazari GA, Kravetz J, Kiupel M, Sledge D, Filho IRB, Montiani-Ferreira F. Ocular squamous cell carcinoma in Holstein cows from the South of Brazil.. Vet World 2017 Dec;10(12):1413-1420.
            doi: 10.14202/vetworld.2017.1413-1420pubmed: 29391681google scholar: lookup
          9. Bocaneti F, Altamura G, Corteggio A, Velescu E, Borzacchiello G. Expression of bcl-2 and p53 in bovine cutaneous fibropapillomas.. Infect Agent Cancer 2015;10(1):2.
            doi: 10.1186/1750-9378-10-2pubmed: 25601891google scholar: lookup
          10. Cotugno R, Gallotta D, d'Avenia M, Corteggio A, Altamura G, Roperto F, Belisario MA, Borzacchiello G. BAG3 protects bovine papillomavirus type 1-transformed equine fibroblasts against pro-death signals.. Vet Res 2013 Jul 22;44(1):61.
            doi: 10.1186/1297-9716-44-61pubmed: 23876161google scholar: lookup
          Subscribe to our newsletter
          Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.